With over 20 candidates in clinical trial, GPC3 is a promising target for the treatment of HCC, leveraging cellular therapeutics such as GPC3-redirected CAR-T [16,47], CAR-NK [48], and CAR-iNKT [49] cells but also noncellular reagents like bispecific antibodies engaging T [50,51,52] and NK cells [53] as well as radiopharmaceuticals [54] and GPC3-derived peptide vaccines [46,55]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.